Phase 2 Breast Cancer Trial, Not Yet Recruiting NCT07255612 Sponsor: Sun Yat-sen University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Not Yet Recruiting

NCT07255612
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older, of any gender.
  • People who have locally advanced or metastatic triple-negative breast cancer (a specific type of breast cancer that has spread or cannot be surgically removed).
  • People who have already received at least two prior chemotherapy treatment courses for their breast cancer (if cancer came back within 12 months after surgery, that chemotherapy counts as one course).
  • People who have at least one area of cancer that can be measured on a scan, according to standard measurement guidelines.
  • People whose blood test results meet specific requirements: sufficient red blood cells, white blood cells, and platelets; healthy kidney function; healthy liver function; and adequate protein levels in the blood (confirm specific numbers with the trial site).
  • People who are reasonably physically active and able to carry out daily activities, based on a standard performance scale scored at 0 or 1 out of 5.
  • People whose doctors expect them to survive for at least 3 months.
  • Women who could potentially become pregnant must have a negative pregnancy blood test during the screening period and must use reliable contraception from signing the consent form until 3 months after the last dose.
  • People who understand the trial and are willing to sign a consent form agreeing to take part.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have been diagnosed with another type of cancer in the 5 years before starting the trial, with some exceptions such as certain types of skin cancer that have been fully treated.
  • People whose major organs (such as heart, liver, or kidneys) are not functioning well enough.
  • People whose cancer has spread into their bone marrow.
  • People who need to receive chemotherapy other than the study drug Eribulin at the same time.
  • People who have had a stroke or a serious heart or blood vessel event in the 6 months before joining the trial.
  • People with certain abnormal heart rhythm readings on an ECG (electrical heart test) during the screening period (confirm specific thresholds with the trial site).
  • People who have previously had a stem cell or bone marrow transplant.
  • People who have received a specific type of medication to boost white blood cell production (G-CSF) within the 2 weeks before joining the trial.
  • People who are allergic to the study drug or any of its ingredients.
  • People whom the trial doctor considers unsuitable to participate for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026

Contact this trial

Phone: 13711277870

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
4 November 2026
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Prevalence of grade 3 neutropenia during cycle 1-2 of chemotherapy treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov